Yuejie Zhang

Name: dblp XML data dump
Creator: Schloss Dagstuhl - Leibniz Center for Informatics
Published: 1993
License: https://creativecommons.org/publicdomain/zero/1.0/
Keywords: dblp, XML, computer science, scholarly publications, metadata

◀ ▶ joint publications with Lina Lu

> Home > Persons > Yuejie Zhang

Publications

2024
[j21]
- view
  authority control:
- export record
  dblp key:
  - journals/npjdm/ZhangLCXLHYPZZM24
- ask others
- share record
  persistent URL:
  - https://dblp.org/rec/journals/npjdm/ZhangLCXLHYPZZM24
Juzhao Zhang, Senlin Lin, Tianhao Cheng, Yi Xu, Lina Lu, Jiangnan He, Tao Yu, Yajun Peng, Yuejie Zhang, Haidong Zou, Yingyan Ma:
RETFound-enhanced community-based fundus disease screening: real-world evidence and decision curve analysis. npj Digit. Medicine 7(1) (2024)
2022
[c69]
- view
  authority control:
- export record
  dblp key:
  - conf/bibm/HouXXZZZLXF22
- ask others
- share record
  persistent URL:
  - https://dblp.org/rec/conf/bibm/HouXXZZZLXF22
Junlin Hou, Jilan Xu, Fan Xiao, Rui-Wei Zhao, Yuejie Zhang, Haidong Zou, Lina Lu, Wenwen Xue, Rui Feng:
Cross-Field Transformer for Diabetic Retinopathy Grading on Two-field Fundus Images. BIBM 2022: 985-990
[i6]
- view
  - electronic edition via DOI (open access)
  - details & citations
  authority control:
- export record
  dblp key:
  - journals/corr/abs-2211-14552
- ask others
- share record
  persistent URL:
  - https://dblp.org/rec/journals/corr/abs-2211-14552
Junlin Hou, Jilan Xu, Fan Xiao, Rui-Wei Zhao, Yuejie Zhang, Haidong Zou, Lina Lu, Wenwen Xue, Rui Feng:
Cross-Field Transformer for Diabetic Retinopathy Grading on Two-field Fundus Images. CoRR abs/2211.14552 (2022)

manage site settings

To protect your privacy, all features that rely on external API calls from your browser are turned off by default. You need to opt-in for them to become active. All settings here will be stored as cookies with your web browser. For more information see our F.A.Q.